<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/" >

<channel>
	<title>PharmaTimes</title>
	<atom:link href="https://pharmatimes.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://pharmatimes.com</link>
	<description>in-depth news, features and insights for the pharmaceutical and healthcare sectors</description>
	<lastBuildDate>Tue, 17 Nov 2026 16:53:50 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://pharmatimes.com/wp-content/uploads/2023/11/PT-icon-150x150.png</url>
	<title>PharmaTimes</title>
	<link>https://pharmatimes.com</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">232894315</site>	<item>
		<title>ViiV wins CHMP backing for paediatric HIV drugs</title>
		<link>https://pharmatimes.com/news/viiv-wins-chmp-backing-for-paediatric-hiv-drugs/</link>
		
		<dc:creator><![CDATA[John Pinching]]></dc:creator>
		<pubDate>Thu, 19 Nov 2026 22:50:00 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://pharmatimes.com/?p=105333</guid>

					<description><![CDATA[<p>Positive opinion supports expanded treatment access</p>
<p><img src="https://pharmatimes.com/wp-content/uploads/2023/11/p32-3.jpg" style="display: block; margin: 1em auto"></p>
]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">105333</post-id>	</item>
		<item>
		<title>Still Time to Secure Your Pass for MAD World Summit 2026</title>
		<link>https://pharmatimes.com/news/still-time-to-secure-your-pass-for-mad-world-summit-2026/</link>
		
		<dc:creator><![CDATA[John Pinching]]></dc:creator>
		<pubDate>Thu, 19 Nov 2026 10:44:00 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://pharmatimes.com/?p=105330</guid>

					<description><![CDATA[<p>Still time to secure your place at MAD World Summit 2026</p>
<p><img src="https://pharmatimes.com/wp-content/uploads/2026/11/MAD-World-Summit-2026-image-scaled.png" style="display: block; margin: 1em auto"></p>
]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">105330</post-id>	</item>
		<item>
		<title>Lexeo reports positive phase 1/2 data for LX2020</title>
		<link>https://pharmatimes.com/news/lexeo-reports-positive-phase-1-2-data-for-lx2020/</link>
		
		<dc:creator><![CDATA[John Pinching]]></dc:creator>
		<pubDate>Wed, 18 Nov 2026 10:38:00 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://pharmatimes.com/?p=105326</guid>

					<description><![CDATA[<p>Regulatory progress supports accelerated approval pathway</p>
<p><img src="https://pharmatimes.com/wp-content/uploads/2023/12/clinical_research.jpg" style="display: block; margin: 1em auto"></p>
]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">105326</post-id>	</item>
		<item>
		<title>Enterprise secures EMA orphan status for CF therapy</title>
		<link>https://pharmatimes.com/news/enterprise-secures-ema-orphan-status-for-cf-therapy/</link>
		
		<dc:creator><![CDATA[John Pinching]]></dc:creator>
		<pubDate>Wed, 18 Nov 2026 10:17:00 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://pharmatimes.com/?p=105325</guid>

					<description><![CDATA[<p>Positive phase 2 data supports ETD001 designation</p>
<p><img src="https://pharmatimes.com/wp-content/uploads/2023/11/lungs.jpg" style="display: block; margin: 1em auto"></p>
]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">105325</post-id>	</item>
		<item>
		<title>Tryngolza approved in EU for severe hypertriglyceridaemia</title>
		<link>https://pharmatimes.com/news/tryngolza-approved-in-eu-for-severe-hypertriglyceridaemia/</link>
		
		<dc:creator><![CDATA[John Pinching]]></dc:creator>
		<pubDate>Tue, 17 Nov 2026 12:55:38 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://pharmatimes.com/?p=105323</guid>

					<description><![CDATA[<p>RNA therapy reduces triglycerides and pancreatitis risk</p>
<p><img src="https://pharmatimes.com/wp-content/uploads/2023/11/22-23.iStock-672081388.jpg" style="display: block; margin: 1em auto"></p>
]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">105323</post-id>	</item>
		<item>
		<title>Sepalna approved in Europe for ovarian cancer</title>
		<link>https://pharmatimes.com/news/sepalna-approved-in-europe-for-ovarian-cancer/</link>
		
		<dc:creator><![CDATA[John Pinching]]></dc:creator>
		<pubDate>Tue, 17 Nov 2026 12:49:03 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://pharmatimes.com/?p=105321</guid>

					<description><![CDATA[<p>New maintenance option after first-line chemotherapy</p>
<p><img src="https://pharmatimes.com/wp-content/uploads/2023/08/approvals.jpg" style="display: block; margin: 1em auto"></p>
]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">105321</post-id>	</item>
		<item>
		<title>Neurizon reaches new HEALEY ALS trial milestone</title>
		<link>https://pharmatimes.com/news/neurizon-reaches-new-healey-als-trial-milestone/</link>
		
		<dc:creator><![CDATA[John Pinching]]></dc:creator>
		<pubDate>Mon, 16 Nov 2026 14:12:27 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://pharmatimes.com/?p=105315</guid>

					<description><![CDATA[<p>First participant enters treatment extension phase</p>
<p><img src="https://pharmatimes.com/wp-content/uploads/2023/12/remote_trial.jpg" style="display: block; margin: 1em auto"></p>
]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">105315</post-id>	</item>
		<item>
		<title>Cancer Grand Challenges launches AI research project</title>
		<link>https://pharmatimes.com/news/cancer-grand-challenges-launches-ai-research-project/</link>
		
		<dc:creator><![CDATA[John Pinching]]></dc:creator>
		<pubDate>Thu, 12 Nov 2026 10:56:47 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://pharmatimes.com/?p=105292</guid>

					<description><![CDATA[<p>£8m initiative to support cancer discovery</p>
<p><img src="https://pharmatimes.com/wp-content/uploads/2024/01/shutterstock_2169745825-scaled.jpg" style="display: block; margin: 1em auto"></p>
]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">105292</post-id>	</item>
		<item>
		<title>GENFIT highlights nangibotide potential in ACLF</title>
		<link>https://pharmatimes.com/news/genfit-highlights-nangibotide-potential-in-aclf/</link>
		
		<dc:creator><![CDATA[John Pinching]]></dc:creator>
		<pubDate>Thu, 12 Nov 2026 10:53:30 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://pharmatimes.com/?p=105290</guid>

					<description><![CDATA[<p>Phase 2 data expected during 2027</p>
<p><img src="https://pharmatimes.com/wp-content/uploads/2026/01/Data_man.jpg" style="display: block; margin: 1em auto"></p>
]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">105290</post-id>	</item>
		<item>
		<title>NICE backs PADCEV and KEYTRUDA combination</title>
		<link>https://pharmatimes.com/news/nice-backs-padcev-and-keytruda-combination/</link>
		
		<dc:creator><![CDATA[John Pinching]]></dc:creator>
		<pubDate>Wed, 11 Nov 2026 10:53:47 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://pharmatimes.com/?p=105291</guid>

					<description><![CDATA[<p>Recommendation expands options for bladder cancer</p>
<p><img src="https://pharmatimes.com/wp-content/uploads/2023/08/NICE.jpg" style="display: block; margin: 1em auto"></p>
]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">105291</post-id>	</item>
	</channel>
</rss>